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Abstract: After lifestyle and behavioral measures to control overactive bladder, the mainstay 
of pharmacological treatment is the use of antimuscarinic therapy. Overactive bladder predomi-
nantly affects older people, who experience the most severe disease, and are also at a greater 
risk of side effects from antimuscarinic therapy. Thus it is imperative that data are available 
on the efﬁ  cacy and tolerability of this group of drugs when used in older people. This article 
reviews the pathophysiology of the condition, its effect on the elderly and the evidence for 
the use of extended release tolterodine in the elderly using data from placebo and active drug 
controlled studies.
Keywords: overactive bladder, tolterodine, urgency incontinence
Introduction
Overactive bladder (OAB) is chronic debilitating disorder characterized by the 
symptoms of urinary urgency with or without urgency incontinence, usually accompa-
nied by frequency and nocturia in the absence of infection or other obvious pathology.1 
These symptoms may result from over activity of the bladder detrusor muscle, spon-
taneous, unprovoked contractions of the detrusor causing urgency or, alternatively, it 
may occur with urethro-vesical dysfunction. Additionally, there has been increasing 
interest in the sensory pathway from the bladder and the role of the urothelium in 
mediating urgency the pathophysiology of the condition over the past few years.2 
Although the condition affects all ages, the prevalence of this condition increases 
with increasing age. In a European and Canadian study the prevalence of OAB was 
estimated as 16.6% in people of 40 years or older, with nocturia and urinary urgency 
being the most commonly reported symptoms.3
For the majority of patients with OAB the underlying etiology remains unknown. 
However, recognized associations include: neurological impairment (multiple sclerosis, 
spinal cord injury), neurological degeneration (Parkinson’s disease, multi-system 
atrophy) and bladder outﬂ  ow tract obstruction.4,5 OAB can be socially disabling and 
it can have a profound effect on the quality of life of individuals, which appears to 
be greater than stress urinary incontinence, which may be related to the unpredict-
ability of the symptoms.6–8 Low self-esteem and embarrassment occur and patients 
may withdraw from social activities and become depressed.9,10 Urgency incontinence 
is associated with an increase in the number of falls and fracture in the elderly 
population.9 Unfortunately, there is a widespread misconception among patients and 
healthcare providers that the symptoms of OAB are due the effects of aging and are 
an inevitable process about which little can be done. This misunderstanding leads to a 
delay in people seeking treatment for their symptoms and to clinicians failing to treat 
patients either seriously or at all, prolonging the suffering associated with the condition. Clinical Interventions in Aging 2009:4 192
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Some data suggest that within the population, older people 
may experience the most severe disease compared with the 
young.12 Unfortunately, the portion of the population in which 
the prevalence of the condition is highest is probably less 
likely to receive active treatment for their condition; this is 
most marked in those who reside in institutional care, where 
under-use is well recognized.
Basis of treatment
The treatment of individuals with OAB involves behavioral, 
pharmacological and surgical interventions which are applied 
according to disease severity and symptom response. Behav-
ioral treatment regimes rely on motivated, agile individuals 
with good cognition but the elderly are not precluded from 
bladder-retraining regimens. It is thought likely that, because 
of their reduced ability to hold on in the face of urgency the 
elderly do not do as well with bladder retraining as a sole 
intervention.10
Pharmacological treatments have to date focused on 
targeting the parasympathetic system which controls motor 
activity and modulates active bladder relaxation during ﬁ  ll-
ing, acting via cholinergic muscarinic receptors. Muscarinic 
receptors can be classiﬁ  ed into 5 subtypes.11 Studies have 
demonstrated that in the human, the detrusor muscle pre-
dominantly contains muscarinic receptors of the M2 and M3 
subtypes.15 In health, the motor innervation to the bladder is 
wholly dependent on the action of acetylcholine acting via 
M3 receptors, although this changes in disease states.
Continence is achieved during the urine storage phase 
by inhibition of the parasympathetic nervous system and 
concurrent activation of the sympathetic nervous system. 
This results in bladder relaxation with co-existent contraction 
of the urethral sphincter. When bladder capacity is reached, 
the pontine micturition center acts as the switch between 
storage and voiding and causes inhibition of the sympathetic 
system and activates the parasympathetic system, resulting 
in relaxation of the urethral sphincter and a sustained bladder 
contraction. The spontaneous contractions of the detrusor, 
while attempting to inhibit micturition thought to be the 
origin of symptoms of urinary frequency and urgency during 
urine storage, are thus the target of current drug therapy.
Anti-muscarinic agents such as oxybutynin, tolterodine, 
propiverine, trospium, solifenacin, darifenacin and fesotero-
dine have thus been developed for the treatment of OAB. 
Although extensive work has been conducted to assess the 
efﬁ  cacy and safety of anti-muscarinics in patients with OAB, 
the majority of studies have focused on a relatively young 
patient population and none have reported results stratiﬁ  ed 
by age. This review addresses the evidence for the safety and 
efﬁ  cacy of anti-muscarinics in the elderly population, concen-
trating upon tolterodine extended release. Other articles have 
reviewed care for the incontinent elderly and other speciﬁ  c 
treatments, but are outside the scope of this article.12–14
Oxbutynin
Oxybutynin immediate release (Oxy-IR) has proven efﬁ  -
cacy for the condition but it has a signiﬁ  cant incidence of 
anti-muscarinic side effects such as dry mouth, constipa-
tion, blurred vision and central nervous system side effects. 
Withdrawal from treatment is a signiﬁ  cant problem, and 
in one observational study only 18% of subjects (women) 
remained on active treatment 6 months following the ini-
tial prescription.15 Of particular concern the effects on the 
central nervous system (CNS) are worrying, and cognitive 
impairment has been noted with oxybutynin.17,18 Oybutynin 
is a relatively small tertiary amine with a high lipophilic-
ity, enabling it to penetrate the blood–brain barrier and 
affect the CNS.16 Oxy-IR is primarily metabolized by the 
cytochrome P-450 system primarily in the liver and the 
upper gastrointestinal tract, resulting in the production of 
the metabolite N-desethyloxybutynin. The active metabolite 
of Oxy-IR, N-desethyloxybutynin, appears to contribute to 
some of the adverse effects, particularly dry mouth, as it acts 
as a competitive antagonist against muscarinic receptors in 
human detrusor muscle and it is present in serum at higher 
dose than the parent compound.17 To reduce the side effect 
proﬁ  le of Oxy-IR an extended release18 and subsequently 
a transdermal preparation were developed.19 Oxybutynin 
extended release is primarily absorbed in the colon where 
there is no cytochrome P-450 system to metabolize it thus 
limiting metabolite production, improving bioavailability and 
an improved side effect proﬁ  le. Likewise, the transdermal 
preparation avoids the ﬁ  rst pass metabolism of oxybutynin, 
reducing the formation of the active metabolite with an asso-
ciated reduction in the incidence of typical antimuscarinic 
side effects.20
Tolterodine
Tolterodine (Tolt-IR) is an established muscarinic antagonist 
effective in the treatment of OAB. Unlike oxybutynin, data 
from animal studies suggest that tolterodine, although a 
non-selective antimuscarinic agent, exhibits preferential 
organ speciﬁ  c selectivity to M2 and M3 muscarinic recep-
tors found in the bladder, accounting for an improved side 
effect proﬁ  le with respect to the occurrence of dry mouth.21 
In a study of alpha wave suppression on the EEG, Tolt-IR Clinical Interventions in Aging 2009:4 193
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did not have a signiﬁ  cant electrophysiological effect when 
compared to oxybutynin.16 Studies have shown that Tolt-IR 
had a comparable efﬁ  cacy to Oxy-IR but it is considerably 
better tolerated.22,23 The safety and efﬁ  cacy of Tolt-IR in 
older patients has been speciﬁ  cally examined. The ﬁ  rst, a 
multi-national, phase 3, randomized, double-blind placebo-
controlled, parallel group study lasting 4 weeks recruited 
177 patients aged 65 and older (115 women, 62 men [mean 
age 75, range 62–92]). Subjects with urgency, urinary 
frequency (8 micturutions per 24 hours), and/or urgency 
incontinence (1 urgency incontinence episode per 24 hours) 
as determined by micturition diaries were eligible for inclu-
sion. The study randomized patients in the ratio of 3:3:2 
to Tolt-IR 1 or 2 mg or placebo respectively. There were 
no clinically relevant changes between the three treatment 
groups in ECG variables or morphology or in laboratory 
parameters. The tolterodine was well tolerated with 87% 
of subjects taking Tolt-IR 1 mg bd, 87% of Tolt-IR 2 mg 
bd completing the study compared with 91% of those on 
placebo. Subjects enrolled in the study were encouraged to 
report adverse events. Dry mouth was the only adverse event 
that occurred signiﬁ  cantly more often in patients treated 
with Tolt-IR (1 mg bd, 30% 2 mg bd, 48%) in comparison 
to the placebo group (9%). The majority of instances of dry 
mouth were mild and moderate in intensity. Three percent 
of Tolt-IR treated subjects withdrew from treatment because 
of dry mouth, compared to 2% of placebo-treated subjects. 
No subject developed acute urinary retention, a side effect 
of considerable concern with anti-muscarinic treatment and 
CNS adverse effects did not occur more frequently in Tolt-IR 
treated patients.
Tolt-IR 2 mg bd was more efﬁ  cacious than placebo in 
improving micturition variables. There was a statistically 
signiﬁ  cant reduction in both the number of micturtions 
per 24 hours (mean reduction –0.7 95% CI –1.1 to –1.3, 
p = 0.0001) and the number of urgency incontinence episodes 
per 24 hours (mean reduction –0.7 95% CI –1.3 to –0.2, 
p = 0.0074) compared to baseline. The volume voided per 
micturition was signiﬁ  cantly greater (mean +16 mL, 95% 
CI, 5–30 mL, p = 0.0099). The mean reduction in inconti-
nence episodes and increase in volume voided per micturition 
were not statistically signiﬁ  cantly different for subjects tak-
ing Tolt-IR 1 mg bd. The ﬁ  ndings from this particular study 
suggest that Tolt-IR was an effective and safe drug in the 
treatment of OAB in older patients at a dose of 2 mg bd and 
was consistent with the recommended dosage of Tolt-IR.24 
The clinical relevance of these ﬁ  ndings is, however, question-
able. The study was extremely short in its design and there 
were no quality of life data by which the clinical relevance 
of the ﬁ  ndings might be judged. In addition, the number of 
subjects was small and they were most likely drawn from a 
population of “ﬁ  tter” elderly. No stratiﬁ  cation of effect by 
age was presented. This study was, however, in its time, a 
signiﬁ  cant advance in knowledge of the effect of these drugs 
in older people.
Tolterodine extended release
The development of tolterodine extended release (Tolt-ER), 
a capsule formation that provides a sustained release over 
24 hours, allowed a once-daily dosing regime. Given the 
relatively low adherence to anti-muscarinics this was thought 
to provide an advantage and would be more convenient to 
patients. Importantly once-daily dosing may be of particular 
beneﬁ  t to older patients in whom adherence to more complex 
drug regimens may be more difﬁ  cult. Once-daily dosing is 
also easier to achieve for statutory services administering 
medication to older frailer people at home. When compared 
to Tolt-IR and placebo in a randomized controlled clinical 
trial of 1529 adult subjects (80% female, mean age 60, range 
20–93) with OAB over 12 weeks,25 both Tolt-IR and Tolt-ER 
were associated with statistically signiﬁ  cant reductions in 
the primary efﬁ  cacy variable in the study, the number of 
incontinence episodes per week, compared with placebo 
(–6.9 ± 15.4), Tolt-ER (–11.8 ± 17.8, p = 0.0001) Tolt-IR 
(–10.6 ± 16.9, p = 0.0005). When the median percentage 
change from baseline in weekly incontinence episodes associ-
ated with Tolt-ER was compared with that associated with 
Tolt-IR, Tolt-ER was found to be more effective (Tolt-ER 
71%, Tolt-IR 60%, p  0.05). The reduction in incontinence 
episodes was accompanied by a reduction in pad usage to one 
pad daily, a 36% reduction from baseline in both groups, sig-
niﬁ  cantly different from placebo (p  0.02 for each group). 
When adverse events in the treatment groups were analyzed, 
only dry mouth was observed at an increased frequency in the 
patients treated with tolterodine in comparison to placebo. 
Patients treated with Tolt-ER had 23% less dry mouth than 
those treated with Tolt-IR (p  0.02). Most instances of dry 
mouth were reported as mild or moderate; only 1.8% of those 
treated with Tolt-ER experienced a severe dry mouth. There 
were no cardiovascular and CNS concerns, suggesting that 
this drug might also be efﬁ  cacious in older people.
A comparison of the older (65 years) and younger 
(65 years) groups from the same study, which addressed 
the efﬁ  cacy, safety and tolerability of Tolt-ER, found a 
comparable reduction in incontinence episodes per week 
between the younger (mean reduction –12.0, SD 17.6) Clinical Interventions in Aging 2009:4 194
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subjects and those 65 years (mean reduction 11.5, SD 
18.2). Both groups of subjects experienced a statistically 
signiﬁ  cant increase in volume voided per micturition com-
pared to placebo (young 35 mL (SD, 33 mL), older 33 mL, 
SD 47 mL). Whereas the Tolt-ER treated subjects 65 years 
experienced a signiﬁ  cant reduction in micturition frequency 
versus placebo, no difference was observed in the older group. 
In an examination of the response to urgency – assessing 
the subject’s ability to ﬁ  nish tasks before voiding –26.2% 
of older subjects treated with Tolt-ER 4 mg experienced 
an improvement in this ability versus 14.8% on placebo 
(p  0.003). After 12 weeks, 69.8% of older Tolt-ER -treated 
subjects considered their treatment to be of beneﬁ  t, versus 
46.9% of those on placebo (p  0.001), signiﬁ  cantly fewer 
than the younger Tolt-ER treated group. Younger patients 
also reported a statistically signiﬁ  cantly greater response to 
placebo treatment than did the older placebo-treated group, 
and thus there was no difference in a between-age group 
analysis of proportionate beneﬁ  t attributable to Tolt-ER 
versus placebo (p = 0.69). Following an analysis of safety in 
subjects receiving at least one dose of study medication in 291 
younger and 214 older subjects, the most common adverse 
events were dry mouth (22.7% young versus 24.3% older), 
headache (8.3% young versus 3.7%, older) and constipation 
(5.9% young versus 6.1% older). The majority of instances 
of dry mouth in the older group were mild or moderate, with 
severe dry mouth reported in 1.9% (versus 1.7% in younger 
subjects). Headache occurred statistically significantly 
more frequently in tolterodine treated subjects younger than 
65 years of age (p = 0.04). There was one case of voiding 
difﬁ  culty in a male subject which resulted in withdrawal from 
the study but no cases of acute urinary retention. Six older 
subjects withdrew because of lack of efﬁ  cacy. CNS adverse 
effects did not occur at a greater rate in subjects older than 
65 years of age.25 Overall, Tolt-ER was efﬁ  cacious and well 
tolerated in the older group of subjects. Of note in this study 
was the lesser (non-drug), placebo response in older subjects. 
This may, as noted by the authors, be due to an effect of medi-
cal co-morbidities negating this effect but may be also due 
to the fact that older people experience more severe disease 
than younger people,12 who may therefore be less likely to 
respond to non-drug intervention.
In terms of quality of life, the longer-term impact of 
Tolt-ER has been examined in two studies including older 
people.26,27 There are, once again, no age-stratiﬁ  ed data yet 
available or any speciﬁ  c studies examining the impact of 
treatment in older people. In the ﬁ  rst, data from a 12-week 
randomized controlled trial of Tolt-ER were analyzed using 
the King’s Health Questionnaire (KHQ) and the Medical 
Outcomes Study Short Form 36-item questionnaire (SF-36). 
Subjects also rated their bladder condition in terms of self-
perceived control. Assessments were performed at baseline 
and at the end of treatment. At end of treatment, KHQ 
domains selected a primary end points (incontinence impact 
and role limitations) signiﬁ  cantly improved (p  0.001) with 
Tolt-ER. Secondary end point domains (physical limitations, 
sleep and energy, severity [coping] measures, and symptom 
severity) were also signiﬁ  cantly improved (p  0.006) after 
treatment with Tolt-ER. The Tolt-ER group had decreased 
symptom severity and statistically signiﬁ  cant improvements 
in patient rating of bladder control compared with the placebo 
group at end of treatment. No treatment differences were 
detected using the SF-36. In the second, related study, KHQ 
data were analyzed from a group of subjects completing a 
12-week randomized controlled phase followed by an open-
label follow up for a year in incontinent OAB sufferers. Data 
were available for 838 subjects (mean age, 61.1 years; 80.9% 
women). The KHQ, signiﬁ  cantly and clinically improved 
from baseline to months 3 and 12 on all domains apart from 
general health perception. Improvements were consistent for 
the 3- and 12-month time frames.
The effect of tolterodine on cognitive function in 
otherwise healthy, cognitively intact older people has been 
assessed, but results are only available as an abstract.28 This 
study, of identical design to those used to assess darifenacin, 
a M3 speciﬁ  c antimuscarinic for OAB,29 found that there was 
no detectable difference in the primary end point, delayed 
face-name recall, between a single dose of Tolt-ER 4 mg 
and Oxy-ER 15 mg. However, there was, in this study, and 




Tolterodine has been the active comparator in a number of 
studies, which although not speciﬁ  cally designed for exam-
ining treatment response in older people, has included older 
subjects, although these would be usually drawn from the 
“young” elderly and would be ﬁ  tter than many. We report 
on these for completion. Tolterodine 2 mg bd has been 
compared to solifenacin in a placebo-controlled 12-week 
study which included 34% subjects over 65 years of age. No 
comparison between older and younger patients was reported 
but tolterodine treatment reduced urinary urgency episodes 
per day by –2.05 from a baseline of 5.45, a difference from 
placebo that did not reach statistical signiﬁ  cance (p = 0.0511). Clinical Interventions in Aging 2009:4 195
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There was likewise no difference between placebo and 
tolterodine in reduction of urgency incontinence episodes and 
all incontinence episodes.30 When compared against Tolt-ER 
in the STAR31 study, a double-blind, double-dummy, two-
arm parallel group trial conducted over a 12-week period was 
analyzed for non-inferiority of solifenacin for the primary 
outcome measure of micturition frequency. Thirty percent 
of included subjects were over 65 years of age and were 
either treated with solifenacin 5 or 10 mg or Tolt-ER 4 mg 
daily. The dose of solifenacin was adjusted after 4 weeks 
according to subject response and request, and placebo was 
added to tolterodine should a dose increase be requested. 
After the achievement of non-inferiority on the primary end 
point, a conventional analysis of secondary variables was 
performed. Solifenacin (5 and 10 mg) was associated with 
a signiﬁ  cant improvement over Tolt-ER in urinary urgency 
(p = 0.035), urgency incontinence episodes (p = 0.001), 
overall incontinence (p = 0.006) and reduction in pad usage 
(p = 0.0023). Moreover, 59% of solifenacin-treated subjects 
who were incontinent according to their 3-day diary data at 
the beginning of the study became continent compared with 
49% of patients of patients treated with Tolt-ER (p = 0.006). 
In an analysis of the solifenacin 5 mg versus tolterodine 
4 mg treated groups over the ﬁ  rst 4 weeks of the study, 
solifenacin was associated with a statistically signiﬁ  cant 
improvement over tolterodine in terms of reduction in 
incontinence episodes per 24 hours (solifenacin –1.30 versus 
tolterodine –0.90, p = 0.0181) and reduction in daily pad use 
(solifenacin –1.21 versus –0.80; p = 0.0089) but in no other 
variable. In terms of adverse events, patients taking solif-
enacin reported a slightly higher number of anti-muscarinic 
side effects than those taking Tolt-ER. However the number 
of patients discontinuing from the study in both groups due 
to adverse events was comparable. Tolt-ER has also been 
compared to Oxy-ER in a 12-week prospective placebo-
controlled study of women with OAB.32 No age stratiﬁ  ed or 
comparative data were provided, but 39.5% of the women 
were over 65 and 15% over the age of 75. Improvements in 
weekly urgency urinary incontinence episodes were similar 
for the women who received Oxy-ER (n = 391) or Tolt-ER 
(n = 399). Oxybutynin was signiﬁ  cantly more effective than 
tolterodine in reducing micturition frequency (p = 0.003), 
and 23.0% of women taking oxybutynin reported no epi-
sodes of urinary incontinence compared with 16.8% of 
women taking tolterodine (p = 0.03). Adverse events were 
generally mild and occurred at low rates, with both groups 
having similar discontinuation of treatment due to adverse 
events. Dry mouth was more common with oxybutynin, but 
tolerability was otherwise comparable, including adverse 
events involving the CNS. These results persisted regard-
less of whether the women were treatment-naive or not.33 In 
a trial of previously treated subjects with urgency or mixed 
urinary incontinence, comparing transdermal oxybutynin 
with placebo and tolterodine ER over 12 weeks, transdermal 
oxybutynin and tolterodine use resulted in equivalent reduc-
tions in the number of daily incontinence episodes, increased 
the average voided volume and improved quality of life 
versus placebo. The commonest adverse event associated 
with transdermal oxybutynin use was localized application 
site pruritis (14 versus 4% for placebo) accompanied by a 
low incidence of systemic anticholinergic side effects (eg, dry 
mouth 4.1%) compared to that occurring with tolterodine 
(7.3% versus 1.7% with placebo).34
In most OAB studies, men are in the minority, and most 
reports are of samples which are approximately 80% female. 
Only in the last 2 to 3 years has there been a speciﬁ  c attempt 
to examine the treatment of OAB in men. With due regard 
to the perceived risk of precipitating acute urinary reten-
tion in men, studies to date have used combination therapy 
with alpha-adrenergic antagonists to address this problem. 
However, once again there are no reports of efﬁ  cacy either 
speciﬁ  cally addressing the elderly or yet providing results 
that are stratiﬁ  ed by age. For example, in a randomized, 
placebo-controlled 12-week study of Tolt-ER, Tolt-ER plus 
tamsulosin and placebo,35 only 23.7% of the 879 subjects 
were over the age of 65 years. A total of 172 men (80%) 
receiving Tolt-ER plus tamsulosin reported treatment beneﬁ  t 
by week 12 compared with 132 patients (62%) receiving pla-
cebo (p  0.001), 146 (71%) receiving tamsulosin (p = 0.06 
versus placebo), or 135 (65%) receiving tolterodine ER 
(p = 0.48 versus placebo). The combination treatment per-
formed better than tolterodine alone in relieving symptoms 
of OAB and in producing signiﬁ  cant improvements on the 
total International Prostate Symptom Score (−8.02 versus 
placebo, −6.19, p = 0.003) and the single quality of life item 
(−1.61 versus −1.17, p = 0.003).
A small randomized, uncontrolled open trial of toltero-
dine 2 mg bd in combination with topical estrogen versus 
tolterodine alone for OAB in post-menopausal women 
showed, in a between-group analysis, signiﬁ  cant improve-
ments in mean daytime frequency and voided volume and 
statistically signiﬁ  cant differences in improvement in quality 
of life as measured by the UDI-6 and IIQ-7 after treatment 
with the combination.36
In conclusion, from what data are available speciﬁ  cally 
for the elderly, tolterodine appears to be efﬁ  cacious in Clinical Interventions in Aging 2009:4 196
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terms of a reduction in objective disease-related variables 
(urinary frequency, urinary urgency episodes and inconti-
nence episodes) and appears to improve quality of life for 
people with the condition, although this is difﬁ  cult to judge 
with limited data. The magnitude of efﬁ  cacy equals that in 
younger subjects for most of these variables. Where toltero-
dine was compared with other active comparators, no data 
have been reported on efﬁ  cacy in the elderly. Where studies 
have included a signiﬁ  cant proportion of older subjects, there 
has been a statistically signiﬁ  cantly greater improvement in 
symptoms with either Oxy-ER or solifenacin. However, these 
differences are most often small and the absolute effect size 
is small. Tolterodine therefore remains an effective and well 
tolerated management option for older people with OAB.
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